IRD jumps more than 30% after gene therapy visual gains update
Shares of Opus Genetics (IRD) surged more than 30% Wednesday, delivering its best-ever single-day gains, after the company said a low dose of its experimental gene therapy showed meaningful improvements in visual function for retinal disease patients.